Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU4T9Y)

• Drug Name: Dimesna Drug Info
• Synonyms: Tavocept (TN)

Indication

Disease Entry	ICD 11	Status	REF
Diabetic nephropathy	GB61.Z	Phase 3	[1]
Lung cancer	2C25.0	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 65625
  CAS Number: CAS 16208-51-8
  TTD Drug ID: DMU4T9Y
  VARIDT Drug ID: DR00091

Molecule-Related Drug Atlas

Drug(s) Transported By Organic anion transporter 1 (SLC22A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[5]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[7]
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[7]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[7]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[8]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[9]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[10]
FLUORESCEIN	DMQTFAO	Ocular disease	1F00.1Z	Approved	[11]

Drug(s) Transported By Organic anion transporter 3 (SLC22A8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[12]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[7]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[13]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[14]
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[15]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[16]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[17]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[18]
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporter 1 (SLC22A6)	DTQ23VB	S22A6_HUMAN	Substrate	[3]
Organic anion transporter 3 (SLC22A8)	DTVP67E	S22A8_HUMAN	Substrate	[3]

References

• [1] BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer. 2002 May;38(8):1148-56.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.
• [4] The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
• [5] Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
• [6] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [7] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [8] Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
• [9] Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
• [10] Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
• [11] Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
• [12] Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
• [13] Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
• [14] Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
• [15] Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
• [16] Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
• [17] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [18] The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
• [19] Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.